In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Helicon Therapeutics Inc.

Latest From Helicon Therapeutics Inc.

2010 Scrip 100 - The peaks and troughs of private investment

The past year has been a rollercoaster of a ride for the private investment market. The US continues to lead the way by a long shot, although robust business strategies have allowed some European biotechs to make their presence felt. And the return of the biotech IPO, while long awaited, is delivering mixed blessings, reports Simon Varcoe.

Cancer Orthopedics

Private investment round-up: July 2009

The number of private companies securing investments took a sizeable leap last month, as a number of small financing rounds added to some heavyweight deal making, a Scrip analysis has found.

Infectious Diseases Canada

Saegis Pharmaceuticals Inc.

Saegis Pharmaceuticals Inc. hopes to be the first to market with therapies for mild cognitive impairment and age-related cognitive decline. Through a combination of in-licensing and internal drug development, it also plans to attack cognitive impairment related to stroke, brain trauma, and other neurological disorders.


The Future of Memory Disorders

The market for products that boost memory and cognition is vast, and underserved. But until clinicians and companies define cognitive diseases and develop clinical models for them, start-ups developing memory drugs face an uncertain future. Included in this feature are profiles of Accera Inc., GBtherapeutics Ltd., Saegis Pharmaceuticals Inc. and Sention Inc.

See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Helicon Therapeutics Inc.
  • Senior Management
  • Kenneth E Johns, Jr., Pres. & CEO
    Tim Tully, PhD, VP, CSO
  • Contact Info
  • Helicon Therapeutics Inc.
    Phone: (858) 246-8120
    7473 Lusk Blvd., Ste. 100
    San Diego, CA 92121